CHEMICON International, Inc. (SERO) Expands Its Exclusive Agreement For Patented Compounds And Methods For Embryonic Stem - ES - Cell Research
10/19/2005 5:13:12 PM
ATLANTA & MELBOURNE, Australia--(BUSINESS WIRE)--April 5, 2005--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, has expanded its exclusive worldwide agreement with Amrad Corporation Ltd (ASX: AML, Melbourne, Australia) and The Walter and Eliza Hall Institute of Medical Research (WEHI, Melbourne, Australia). The new agreement provides Chemicon additional rights to further develop its proprietary embryonic stem cell products, Leukemia Inhibitory Factor (LIF) and ESGRO(R) into additional kits and combination products. This new agreement provides an important expansion of the initial license agreement covering LIF patent rights signed by Chemicon, Amrad and WEHI in 1999 to include additional fields of use in non-therapeutic fields.
The new license affirms Chemicon's exclusive rights to develop, manufacture, sublicense and distribute LIF and LIF based products in the research market worldwide and expands the company's ability to develop, manufacture and commercialize diagnostic products. The new exclusive license also gives Chemicon access to patents and applications that cover LIF production and uses in various biotechnology applications. Through this agreement, Chemicon expands its rights to access Amrad's LIF and embryonic stem cell intellectual property portfolio, which now totals 45 granted and 7 pending patents for both LIF and ESGRO(R) applications. Amrad has retained all other rights under the LIF patents and patent applications for therapeutic applications and associated research activities.